Articles related to LIVER CANCER

The STRIDE regimen demonstrated a 30.7% survival rate at 36 months, compared to 20.2% with sorafenib, suggesting potential long-term benefits for patients with unresectable hepatocellular carcinoma.

Understanding liver cancer’s complexities is crucial in guiding patients towards effective treatment and preventive measures. This overview sheds light on the pivotal aspects of managing liver cancer, from symptoms to therapy options.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Abdominal cancer is no longer an ailment confined to older demographics, with a notable uptick in cases among younger adults. Physicians are urged to consider early screening, especially for patients with familial cancer histories, amidst growing concerns over lifestyle and environmental influences.

Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.

In this Phase 3 trial, resmetirom demonstrated a notable capacity to induce NASH resolution and improve liver fibrosis, offering hope for a therapeutic breakthrough in a field with limited treatment options. This study emphasizes the importance of advancing research in liver-directed therapies for NASH.